10/27/2021 | Press release | Distributed by Public on 10/27/2021 09:49
BERWYN, Pa. - Troutman Pepper client Context Therapeutics Inc., a women's oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, announced the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $28.75 million. Read the company's press release announcing the IPO.
Troutman Pepper Partner Daniel M. Scolnick advised Context Therapeutics on all intellectual property issues related to the IPO. Scolnick is a registered patent attorney with a PhD in biochemistry and biophysics who guides clients of all sizes on how to best protect and defend their life sciences intellectual property assets. Scolnick was supported by associate and registered patent attorney, George Liu.
Troutman Pepper's Intellectual Property Practice Group consists of a nationally ranked team of attorneys, patent agents and other professionals and provides counsel on the development, acquisition, management, and monetization of a company's most important assets. Clients range from first-time inventors to multinational industry leaders.
About Troutman Pepper
Troutman Pepper is a national law firm with more than 1,200 attorneys strategically located in 23 U.S. cities. The firm's litigation, transactional, and regulatory practices advise a diverse client base, from start-ups to multinational enterprises. The firm provides sophisticated legal solutions to clients' most pressing business challenges, with depth across industry sectors, including construction, energy, finance, health sciences, insurance, private equity, real estate, and technology, among others. Learn more at troutman.com.